Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Pulmonary Embolism Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Pulmonary Embolism Overview | 7 | 1 |
| Pipeline Products for Pulmonary Embolism Comparative Analysis | 8 | 1 |
| Pulmonary Embolism Therapeutics under Development by Companies | 9 | 1 |
| Pulmonary Embolism Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Pulmonary Embolism Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Pulmonary Embolism Products under Development by Companies | 13 | 1 |
| Pulmonary Embolism Products under Investigation by Universities/Institutes | 14 | 1 |
| Pulmonary Embolism Companies Involved in Therapeutics Development | 15 | 4 |
| Accu-Break Pharmaceuticals, Inc. | 15 | 1 |
| Dong-A Socio Holdings Co. Ltd. | 16 | 1 |
| F. Hoffmann-La Roche Ltd. | 17 | 1 |
| Genentech, Inc. | 18 | 1 |
| Pulmonary Embolism Therapeutics Assessment | 19 | 9 |
| Assessment by Monotherapy Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 6 |
| Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders Drug Profile | 28 | 1 |
| STP-023725 Drug Profile | 29 | 1 |
| tenecteplase Drug Profile | 30 | 1 |
| TMS-007 Drug Profile | 31 | 1 |
| TRX-1 Drug Profile | 32 | 1 |
| warfarin potassium Drug Profile | 33 | 1 |
| Pulmonary Embolism Dormant Projects | 34 | 1 |
| Pulmonary Embolism Discontinued Products | 35 | 1 |
| Pulmonary Embolism Product Development Milestones | 36 | 14 |
| Featured News &Press Releases | 36 | 1 |
| Apr 25, 2016: Patent Term for Rivaroxaban Extended in US | 36 | 1 |
| Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials | 36 | 1 |
| Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy | 37 | 1 |
| Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting | 38 | 1 |
| Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO | 38 | 2 |
| Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE | 40 | 1 |
| Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy | 40 | 2 |
| Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014 | 42 | 1 |
| Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE | 42 | 2 |
| Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE | 44 | 1 |
| May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism | 44 | 1 |
| Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention | 45 | 1 |
| Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE | 46 | 1 |
| Dec 03, 2013: New Data to be Presented on Bayer s Xarelto Single-Drug Solution for the Treatment and Prevention of Recurrent Pulmonary Embolism and Deep Vein Thrombosis | 47 | 1 |
| Sep 20, 2013: Pooled Analysis Confirms XARELTO has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE | 47 | 3 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |